Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | $17.00 | Outperform | Oppenheimer |
D - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
D - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )) today announced that the Company entered into a securities purchase agreement ("Agreement") with investor David Lazar ("Lazar"), pursuant to which he agreed to purchase from the Company 1,000,000 shares of Series C Convertible Preferred Stock (the "C Preferred Stock") and 2,100,000 shares of Series D Convertible Preferred Stock (the "D Preferred Stock") of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, subject to the terms and conditions of the Agreement. The proceeds of the transaction will
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder. The Company's Board of Directors is reviewing a range of appropriate strategies to realize value from its assets. The Board has directed management to
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form
Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00
Oppenheimer initiated coverage of Cyclacel Pharmaceuticals with a rating of Outperform and set a new price target of $17.00
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have Brian join Cyclacel as CMO. His extensive clinical and product development experience in oncology and hematology further adds to the strengths of our team and will support our efforts
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures– BERKELEY HEIGHTS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021. The Company will present at Biotech Showcase™ Digital 2021 taking place virtually from Januar
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
3 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
SC 13G - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. "We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), in Barcelona, Spain. The patients were enrolled in
- Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well -- 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today second quarter financial results and provided a business update. "Following oral fadraciclib data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the Phase 2 stage of our 065-101 study is enrolling well,
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call: (203) 518-9708 Archive: (800) 934-7884 / international archive: (402) 220-6987 Code for live and archived conference call is CYCCQ224. Webcast link For the live and archived webcast,